Saltar al contenido principal

ETHNOS_APP

Inicio • Búsqueda • Revistas • Lista 0

Factor Analysis in Distinguishing Coronavirus Disease 2019 From Other Influenza-like Illness Using a Validated Patient-Reported Outcome Instrument FLU-PRO Plus

A Prospective Real-world Cohort Study

Datos Bibliográficos

ID9102871
AutoresElla A Chrenka (0000-0002-3750-7062, HealthPartners Institute, Bloomington, MN, autor de correspondencia), Douglas W Roblin (Kaiser Permanente Mid-Atlantic, Rockville, MD), Jennifer C Gander (0000-0002-4798-0750, Kaiser Permanente Georgia, Atlanta, GA), John H Powers (0000-0002-5150-5119, Frederick National Laboratory for Cancer Research), Lee X Cromwell (Kaiser Permanente Georgia, Atlanta, GA), Prasanthi X Kodthala (HealthPartners Institute, Bloomington, MN), Prasanthi Kodthala (H ea lt hP ar tn er s, autor de correspondencia), Thomas S Whiting (Kaiser Permanente Mid-Atlantic, Rockville, MD), Thomas Whiting (Kaiser Permanente), Musu M Sesay (Kaiser Permanente Georgia, Atlanta, GA), Musu Sesay (0000-0002-8150-6753, Kaiser Permanente), Marni F Segall (Kaiser Permanente Georgia, Atlanta, GA), Marni Segall (Kaiser Permanente), Adrienne N Deneal (Kaiser Permanente Mid-Atlantic, Rockville, MD), Adrienne Deneal (Kaiser Permanente), Anjali R Truitt (0000-0003-1509-0072, HealthPartners Institute, Bloomington, MN, autor de correspondencia), Elanadora U Sour (HealthPartners Institute, Bloomington, MN, autor de correspondencia), Brian C Martinson (0000-0002-4255-5595, HealthPartners Institute, Bloomington, MN, autor de correspondencia)
Año2023
Volumen61
Número5
Páginas288-294
Fecha de publicación2023-05-01
Peer ReviewedSí
Open AccessNo
TipoARTICLE
RevistaMedical Care (JOURNAL)
Identificadores de la revistaISSN: 0025-7079 • E-ISSN: 1537-1948
EditorialOvid Technologies (Wolters Kluwer Health) (PUBLISHER)
DOI10.1097/mlr.0000000000001842
PMID36917774
OpenAlexW4324131596
IdiomaEN
Referencias citadas9

BACKGROUND/OBJECTIVE: InFLUenza Patient-reported Outcome (FLU-PRO Plus) is a 34-item patient-reported outcome instrument designed to capture the intensity and frequency of viral respiratory symptoms. This study evaluates whether FLU-PRO Plus responses could discriminate between symptoms of coronavirus disease 2019 (COVID-19) and influenza-like illness (ILI) with no COVID diagnosis, as well as forecast disease progression. METHODS: FLU-PRO Plus was administered daily for 14 days. Exploratory factor analysis was used to reduce the FLU-PRO Plus responses on the first day to 3 factors interpreted as "symptom clusters." The 3 clusters were used to predict COVID-19 versus ILI diagnosis in logistic regression. Correlation between the clusters and quality of life (QoL) measures was used to assess concurrent validity. The timing of self-reported return to usual health in the 14-day period was estimated as a function of the clusters within COVID-19 and ILI groups. RESULTS: Three hundred fourteen patients completed day 1 FLU-PRO Plus, of which 65% had a COVID-19 diagnosis. Exploratory factor analysis identified 3 symptom clusters: (1)general Body, (2) tracheal/bronchial, and (3) nasopharyngeal. Higher nasopharyngeal scores were associated with higher odds of COVID-19 compared with ILI diagnosis [adjusted odds ratio = 1.61 (1.21, 2.12)]. Higher tracheal/bronchial scores were associated with lower odds of COVID-19 [0.58 (0.44, 0.77)]. The 3 symptom clusters were correlated with multiple QoL measures ( r = 0.14-0.56). Higher scores on the general body and tracheal/bronchial symptom clusters were associated with prolonged time to return to usual health [adjusted hazard ratios: 0.76 (0.64, 0.91), 0.80 (0.67, 0.96)]. CONCLUSION: Three symptom clusters identified from FLU-PRO Plus responses successfully discriminated patients with COVID-19 from non-COVID ILI and were associated with QoL and predicted symptom duration

Disease · Logistic regression · Odds · Odds ratio · Physical therapy · Quality of life (healthcare) · Respiratory disease · Severity of illness · COVID-19 Clinical Research Studies · Internal Medicine · Long-Term Effects of COVID-19 · Medicine · Respiratory viral infections research

Velocidad de citaciónhistorical
Altamente citadoNo
Ethnos_APP • Proyecto Open Source • Licencia MIT • Frontend v2.0.0 • Privacidad y Cookies • Documentación de la API: api.ethnos.app/docs • Código de la API: GitHub • DOI: 10.5281/zenodo.17049435 • Código del Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae